Invivyd to Participate in Upcoming September Investor Conferences
Invivyd management plans fireside chats and meetings at three New York investor conferences, with webcast access via the company’s investor website.
Rhea-AI Summary
Invivyd (IVVD) will participate in three investor conferences in New York in September 2026, featuring Chairman and CEO Marc W. Elia and other management members.
The company will attend Citi’s 2026 Biopharma Back to School Conference on September 9 (meetings only), the Cantor Global Healthcare Conference with a fireside chat on September 10 at 9:45 AM ET, and the H.C. Wainwright 28th Annual Global Investment Conference with a fireside chat on September 14 at 5:00 PM ET. Live webcasts of the fireside chats will be accessible and archived in the investor section of Invivyd’s website.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HAVEN, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc W. Elia, Chairman and Chief Executive Officer, and members of company management will participate in three upcoming investor conferences:
Citi’s 2026 Biopharma Back to School Conference
Wednesday, September 9, 2026 (Meetings Only)
Location: New York, NY
2026 Cantor Global Healthcare Conference
Fireside Chat: Thursday, September 10, 2026 at 9:45 AM ET (Webcast Link)
Meetings to Follow
Location: New York, NY
H.C. Wainwright 28th Annual Global Investment Conference
Fireside Chat: Monday, September 14, 2026 at 5:00 PM ET (Webcast Link)
Meetings Prior to Fireside Chat
Location: New York, NY
Live webcasts of the fireside chats will be available via the investor section of Invivyd’s website at investors.invivyd.com and will be archived following each event.
The management team will host investor meetings at the conferences. Investors participating in these events who are interested in meeting with Invivyd management should contact their Citi, Cantor, or H.C. Wainwright representatives.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Contacts:
Media Relations
(781) 208-0160
media@invivyd.com
Investor Relations
(781) 208-1747
investors@invivyd.com
FAQ
How can investors access the Invivyd fireside chat webcasts?
Live webcasts of Invivyd’s fireside chats at the Cantor and H.C. Wainwright conferences will be available through the investor section of the company’s website at investors.invivyd.com, and will be archived there after each event.
How can investors request meetings with Invivyd management at these conferences?
Investors participating in the Citi, Cantor, or H.C. Wainwright conferences who wish to meet with Invivyd management should contact their respective Citi, Cantor, or H.C. Wainwright representatives.